Edgestream Partners L.P. Has $331,000 Holdings in Edwards Lifesciences Corporation (EW)

Edgestream Partners L.P. lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 38.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,028 shares of the medical research company’s stock after selling 1,878 shares during the period. Edgestream Partners L.P.’s holdings in Edwards Lifesciences Corporation were worth $331,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of EW. ETF Managers Group LLC purchased a new stake in shares of Edwards Lifesciences Corporation during the 2nd quarter valued at $112,000. Shine Investment Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences Corporation during the 2nd quarter valued at $126,000. Cornerstone Advisors Inc. lifted its holdings in shares of Edwards Lifesciences Corporation by 25.1% during the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 219 shares during the last quarter. Alexandria Capital LLC lifted its holdings in shares of Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 19 shares during the last quarter. Finally, MPS Loria Financial Planners LLC purchased a new stake in shares of Edwards Lifesciences Corporation during the 2nd quarter valued at $140,000. Institutional investors own 82.37% of the company’s stock.

In other news, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $115.99, for a total transaction of $3,816,071.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Larry L. Wood sold 18,960 shares of the business’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $111.81, for a total transaction of $2,119,917.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 171,480 shares of company stock worth $18,855,915. Company insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. The firm had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. During the same quarter last year, the firm earned $0.68 earnings per share. The company’s revenue was up 11.1% compared to the same quarter last year.

Several analysts have recently commented on the company. Canaccord Genuity reiterated a “buy” rating and set a $155.00 price objective on shares of Edwards Lifesciences Corporation in a report on Sunday, October 8th. Cowen and Company reiterated a “buy” rating and set a $135.00 price objective on shares of Edwards Lifesciences Corporation in a report on Thursday, October 12th. Barclays PLC decreased their price objective on Edwards Lifesciences Corporation from $120.00 to $118.00 and set an “equal weight” rating for the company in a report on Wednesday, October 25th. BidaskClub lowered Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a report on Friday, August 25th. Finally, Zacks Investment Research lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a report on Monday, July 17th. Seven research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $125.17.

COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.com-unik.info/2017/11/03/edgestream-partners-l-p-has-331000-holdings-in-edwards-lifesciences-corporation-ew.html.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

What are top analysts saying about Edwards Lifesciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edwards Lifesciences Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit